Zimmer Biomet (ZBH) PT Raised to $150 at Oppenheimer Due to MyMobility App Digital Health

Zimmer Biomet (ZBH) PT Raised to $150 at Morgan Stanley

Morgan Stanley analyst David Lewis raised the price target on Zimmer Biomet (NYSE: ZBH) to $150.00 (from $140.00) while maintaining a Overweight rating.... More

Companies with NDRs 8/05

Companies with non-deal roadshows or company visits/marketing with sell-side today:

AB InBev SA (NYSE: BUD) Mizuho NDR Virtual

Acer Therapeutics (NASDAQ: ACER) Roth Capital NDR Virtual

Brainsway Ltd. (NASDAQ: BWAY) Cantor Fitzgerald NDR... More

Zimmer Biomet (ZBH) PT Raised to $150 at Raymond James

Raymond James analyst Lawrence Keusch raised the price target on Zimmer Biomet (NYSE: ZBH) to $150.00 (from $140.00) while maintaining a Strong Buy rating.... More

Zimmer Biomet (ZBH) PT Raised to $169 at UBS

UBS raised its price target on Zimmer Biomet (NYSE: ZBH) to $169.00 (from $165.00) while maintaining a Buy rating.... More

Zimmer Biomet (ZBH) PT Raised to $155 at Stifel After Orthopedic Procedures Rebound

Stifel analyst Rick Wise raised the price target on Zimmer Biomet (NYSE: ZBH) to $155.00 (from $130.00) after 2Q20 results reinforced the long-term bullish Zimmer thesis including encouraging end-of-2Q recovery trends, and managements emphatic confidence in Zimmers long-term growth strategy.

The analyst reiterated... More

Zimmer Biomet (ZBH) PT Raised to $139 at BTIG

BTIG analyst Ryan Zimmerman raised the price target on Zimmer Biomet (NYSE: ZBH) to $139.00 (from $132.00) while maintaining a Buy rating.... More

Zimmer Biomet (ZBH) PT Raised to $153 at SVB Leerink

SVB Leerink analyst Richard Newitter raised the price target on Zimmer Biomet (NYSE: ZBH) to $153.00 (from $146.00) while maintaining a Outperform rating.... More

Zimmer Biomet (ZBH) PT Raised to $150 at Jefferies

Jefferies analyst Raj Denhoy raised the price target on Zimmer Biomet (NYSE: ZBH) to $150.00 (from $137.00) while maintaining a Buy rating.... More

Zimmer Biomet Holdings (ZBH) Tops Q2 EPS by 78c

Zimmer Biomet Holdings (NYSE: ZBH) reported Q2 EPS of $0.05, $0.78 better than the analyst estimate of ($0.73). Revenue for the quarter came in at $1.23 billion versus the consensus estimate of $909.41 million.

Financial Guidance

While Zimmer Biomet saw encouraging recovery in elective procedures during the second... More